Our team is made up of over 240 dedicated scientists, process engineers, operators, quality staff and more. Nearly 60 employees have PhDs. They bring years of extensive experience in regenerative medicine and biopharmaceutical development and manufacturing.

CCRM’s scientific expertise, coupled with our approach to project management, allows us to work collaboratively with both emerging biotech start-ups and academic as they begin to take their products from concept to market. CCRM’s development, scale-up/out and manufacturing capabilities include:

  • Good Manufacturing Practices (GMP), induced pluripotent stem cell (iPSC) reprogramming, gene editing and differentiation
  • Automated, closed, integrated, process development (PD) and manufacturing for T-cells and natural killer (NK) cells (e.g. CAR-T, CAR-NK)
  • Viral vector (lentivirus, adeno-associated virus, other) upstream and downstream process development and optimization for manufacturing
  • GMP-compliant manufacturing of master/working cell banks
  • Analytical development including high-throughput screening assays, quality control (QC) testing, and ICH stability studies
  • Assessment of next-generation bioprocessing hardware and technologies
  • Custom and high-throughput media development
  • Hematopoietic stem cell isolation and processing
  • Cryopreservation strategies
  • In-house QC to support product release

Find out more about our extensive expertise

 

 

Learn more about the other pillars in our approach:

Customer Testimonials

We’ve found an ongoing partner [in CCRM] – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta

[The team] really helped us get to where we are today. – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics

It almost felt like they [CCRM] were an extension of our team. The culture and adaptive nature, flexibility and communication were excellent. – Edel O’Toole, Senior Director Project & Vendor Management, Avectas

Read our latest blog posts